RAS (Rat Sarcoma Virus) Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

RAS (Rat Sarcoma Virus) is a viral oncogene that plays a crucial role in the development of certain cancers. It is a mutated form of the RAS gene found in rats, and its mechanism of action involves the activation of signaling pathways that promote cell growth and division. RAS is primarily associated with various cancer indications, including colorectal cancer, lung cancer, pancreatic cancer, and melanoma. According to the World Health Organization (WHO), colorectal cancer is the third most commonly diagnosed cancer worldwide, with approximately 1.93 million new cases reported in 2020. In Europe, there were an estimated 494,000 new cases of colorectal cancer, while the United States witnessed around 147,950 new cases in the same year Lung cancer remains the leading cause of cancer-related deaths globally, with approximately 1.80 million deaths reported in 2020. In Europe, lung cancer accounted for 430,000 deaths, while the United States reported around 135,720 deaths due to lung cancer in the same year. Pancreatic cancer has a particularly poor prognosis, with a five-year survival rate of around 10%. In the United States, pancreatic cancer accounted for an estimated 60,430 new cases and 48,220 deaths in 2020, as reported by the American Cancer Society.

Growth drivers of the RAS market include the need for effective targeted therapies against RAS-driven cancers and the continuous investment in research and development efforts to unravel the complexities of RAS biology and develop novel treatment approaches. Companies such as Novartis, Amgen, Mirati, Immunitybio, Innoviva, Golden Biotechnology, Genfleet Therap, Jacobio Pharma, and Roche cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, Innovia is currently conducting a clinical trial of the drug LJPC-501 for the treatment of leukemia.

Key Developments

  • In May 2023, Novartis Pharmaceuticals completed a phase-II trial of Rydapt in Acute myeloid leukemia in Hong Kong, South Korea, Russia, Taiwan, Thailand, Vietnam and Japan.
  • In Oct 2020, Amgen presented safety and efficacy data from a phase Ib/II CodeBreak 101 trial of Lumykras in solid tumors at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023).

Approved RAS Molecules

  • Rydapt (midostaurin)
  • Lumakras (sotorasib)
  • Estybon (rigosertib)
  • Krazati (adagrasib)

RAS Pipeline Molecules

  • Giapreza (LJPC-501)
  • GFH925
  • glecirasib (JAB-21822)
  • opnurasib (JDQ443)
  • divarasib (RG6330)
  • D-1553
  • JAB-3312
  • LY3537982
  • diazepinomicin (AMO-01)
  • ELI-002
  • PRLX 93936
  • library TCR-T-cell therapy
  • perillyl alcohol (NEO100)      

Clinical Activity and Development of RAS

In the RAS space, more than 20 companies are conducting more than 400 clinical trials in this category of drugs. For instance,

  • In Dec 2022, Novartis presented pharmacodynamics and efficacy data from a phase II trial of Rydapt in acute myeloid leukemia at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
  • In June 2023, Novartis presented efficacy data from the phase iii unify trial Rydapt in acute myeloid leukemia at the 27th Congress of the European Haematology Association (EHA-2022)

Product Name

Total Studies

Giapreza (LJPC-501)




glecirasib (JAB-21822)


opnurasib (JDQ443)


divarasib (RG6330)








diazepinomicin (AMO-01)




PRLX 93936


library TCR-T-cell therapy


perillyl alcohol (NEO100)


Target Indication Analysis of RAS

RAS (Rat Sarcoma Virus) has been primarily studied and targeted in various cancer indications. One significant target indication for RAS is colorectal cancer, where RAS mutations are commonly found and associated with resistance to certain treatments. Additionally, RAS mutations are prevalent in lung cancer, particularly in non-small cell lung cancer, making it another important target indication. Pancreatic cancer, known for its aggressive nature and limited treatment options, also presents a potential target for RAS-focused therapies. Furthermore, RAS mutations have been observed in melanoma, a type of skin cancer, which opens up possibilities for targeted interventions. The identification and development of effective treatments for these RAS-driven cancers remain crucial in improving patient outcomes and advancing cancer therapeutics

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario


Frequently Asked Questions

RAS drugs are used in the management of colorectal cancer, non-small cell lung cancer, pancreatic cancer.

The growth drivers of the RAS market include the urgent need for effective treatments for RAS-driven cancers, which pose significant challenges due to their aggressive nature and resistance to conventional therapies. The expanding knowledge of RAS biology and the identification of new therapeutic targets offer opportunities for innovative drug development. Additionally, the advancements in precision medicine and personalized therapies create a favorable landscape for the utilization of RAS as a target for tailored cancer treatments.

The major players in this space are Novartis, Amgen, Mirati, Immunitybio, Innoviva, Golden Biotechnology, Genfleet Therap, Jacobio Pharma, and Roche.

The market for Rat Sarcoma Virus (RAS) faces significant restraints due to the potential health risks associated with its use, regulatory restrictions on its application in research and clinical settings, and the availability of alternative methods and technologies for studying cancer and related diseases. Additionally, the limited understanding of RAS biology and the complexities of developing targeted therapies specifically for RAS-driven cancers pose challenges in the market's growth and adoption.

  • Novartis
  • Amgen
  • Mirati
  • Immunity Bio
  • Innoviva
  • Golden Biotechnology
  • Genfleet Therapy
  • Jacobio Pharma
  • Roche
  • Inventisbio
  • Jacobio Pharma, Abbvie
  • Eli Lilly
  • Elicio Therapy
  • Silenseed
  • Prolexys
  • Shanghai Yingli Pharma
  • Alaunos Therapy
  • Neonc Technologies
  • Astellas
  • AstraZeneca
  • Boehringer Ingelheim
  • Betta Pharma